NCT06898853View on ClinicalTrials.gov

The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Dry Eye Disease (DED)
Interventions
DRUG

0.1% Ciclosporin A eye drops

The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)

DRUG

Mineral oils eye drops

This arm is the comparator arm has mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)

Trial Locations (1)

2033

School of Optometry and Vision Science, Sudney

All Listed Sponsors
collaborator

University of Melbourne

OTHER

lead

The University of New South Wales

OTHER

NCT06898853 - The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | Biotech Hunter | Biotech Hunter